Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts
-
Published:2023-05-18
Issue:1
Volume:7
Page:
-
ISSN:2397-768X
-
Container-title:npj Precision Oncology
-
language:en
-
Short-container-title:npj Precis. Onc.
Author:
Sturtzel C., Grissenberger S.ORCID, Bozatzi P., Scheuringer E., Wenninger-Weinzierl A., Zajec Z., Dernovšek J., Pascoal S.ORCID, Gehl V.ORCID, Kutsch A., Granig A., Rifatbegovic F.ORCID, Carre M.ORCID, Lang A., Valtingojer I., Moll J., Lötsch D., Erhart F., Widhalm G.ORCID, Surdez D., Delattre O., André N., Stampfl J., Tomašič T.ORCID, Taschner-Mandl S.ORCID, Distel M.ORCID
Abstract
AbstractZebrafish xenotransplantation models are increasingly applied for phenotypic drug screening to identify small compounds for precision oncology. Larval zebrafish xenografts offer the opportunity to perform drug screens at high-throughput in a complex in vivo environment. However, the full potential of the larval zebrafish xenograft model has not yet been realized and several steps of the drug screening workflow still await automation to increase throughput. Here, we present a robust workflow for drug screening in zebrafish xenografts using high-content imaging. We established embedding methods for high-content imaging of xenografts in 96-well format over consecutive days. In addition, we provide strategies for automated imaging and analysis of zebrafish xenografts including automated tumor cell detection and tumor size analysis over time. We also compared commonly used injection sites and cell labeling dyes and show specific site requirements for tumor cells from different entities. We demonstrate that our setup allows us to investigate proliferation and response to small compounds in several zebrafish xenografts ranging from pediatric sarcomas and neuroblastoma to glioblastoma and leukemia. This fast and cost-efficient assay enables the quantification of anti-tumor efficacy of small compounds in large cohorts of a vertebrate model system in vivo. Our assay may aid in prioritizing compounds or compound combinations for further preclinical and clinical investigations.
Funder
Österreichische Forschungsförderungsgesellschaft OeAD-GmbH Österreichischen Akademie der Wissenschaften Comprehensive Cancer Center Forschungsförderung der Initiative Krebsforschung, MedUni Wien Vienna Science and Technology Fund EC | Horizon 2020 Framework Programme Javna Agencija za Raziskovalno Dejavnost RS Sanofi
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference53 articles.
1. WHO, “Cancer”, https://www.who.int/news-room/fact-sheets/detail/cancer (2022). 2. Xu, C., Li, X., Liu, P., Li, M. & Luo, F. Patient-derived xenograft mouse models: a high fidelity tool for individualized medicine. Oncol Lett 17, 3–10 (2019). 3. Costa, B., Estrada, M. F., Mendes, R. V. & Fior, R. Zebrafish avatars towards personalized medicine—a comparative review between avatar models. Cells 9, https://doi.org/10.3390/cells9020293 (2020). 4. Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl Acad. Sci. USA 114, E8234–E8243 (2017). 5. Lee, L. M., Seftor, E. A., Bonde, G., Cornell, R. A. & Hendrix, M. J. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev. Dyn. 233, 1560–1570 (2005).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|